Skip to main content

OliX Pharmaceuticals Presents New Data on Asymmetric siRNA Therapy at TIDES: Oligonucleotides and Peptide Therapeutics 2020 Virtual Conference

Written by Customer Service on . Posted in Public Companies.

SUWON, Korea, Sept. 15, 2020 (GLOBE NEWSWIRE) — OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today presented a poster at the TIDES: Oligonucleotides and Peptide Therapeutics 2020 Virtual Conference. The presentation entitled, “Asymmetric siRNA Therapeutics by OliX Pharmaceuticals,” highlights OliX’ proprietary asiRNA platform technology along with the preclinical/clinical development of various programs.
The Company presented the clinical development status of OLX101A, a cell-penetrating asymmetric siRNA (cp-asiRNA) targeting hypertrophic and keloid scars. OliX also presented data on ophthalmic pipelines that demonstrate the efficacy of OLX301A, targeting wet and dry age-related macular degeneration (AMD) in rodents and non-human primate disease models. In addition, OLX301D, targeting subretinal fibrosis and wet AMD, showed efficacy in relevant animal models. The Company also showcased data for its GalNAc-asiRNA platform technology for the treatment of liver diseases.The presentation can be found on TIDES website https://tidesus2020.eventfinity.co/directories/17271/attendee/284822387.“This data further validates OliX’ asiRNA technology and its ability to work across a number of therapeutic development platforms as the next generation RNAi trigger,” said Dong Ki Lee, Ph.D., founder and Chief Executive Officer. “We are thrilled to present this data at the TIDES 2020 virtual conference.”About OliX PharmaceuticalsOliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes, based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered as the most efficient gene silencing technology. Based on asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target locally administrable diseases, such as hypertrophic scar, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, idiopathic pulmonary fibrosis (IPF), and neuropathic pain. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.To learn more about the company, visit https://www.olixpharma.com/eng/
To learn more about RNAi technology, visit https://www.olixpharma.com/eng/rnd/rnd01.phpAsymmetric small interfering RNA (asiRNA) is the next generation of RNAi therapeutics that offers efficient gene regulation. In comparison to existing siRNA therapeutics, OliX Pharmaceutical’s asiRNA shows comparable gene silencing and significantly reduce siRNA-mediated side effects such as off-target gene silencing and immune stimulation. Media Contact:Surabhi Verma
Westwicke/ICR PR
Phone: +1.646.677.1825
Surabhi.Verma@westwicke.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.